Sowell Financial Services LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 9.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 48,301 shares of the company’s stock after purchasing an additional 3,985 shares during the period. Sowell Financial Services LLC’s holdings in AbbVie were worth $12,635,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of ABBV. One Wealth Capital Management LLC increased its position in shares of AbbVie by 308.3% in the third quarter. One Wealth Capital Management LLC now owns 4,781 shares of the company’s stock valued at $1,251,000 after buying an additional 3,610 shares in the last quarter. Evergreen Capital Management LLC raised its stake in shares of AbbVie by 11.1% during the 3rd quarter. Evergreen Capital Management LLC now owns 57,672 shares of the company’s stock worth $15,086,000 after buying an additional 5,756 shares during the period. Altura Wealth Advisors Inc. lifted its position in shares of AbbVie by 11.7% during the 3rd quarter. Altura Wealth Advisors Inc. now owns 9,773 shares of the company’s stock valued at $2,556,000 after buying an additional 1,025 shares in the last quarter. James J. Burns & Company LLC lifted its position in shares of AbbVie by 6.8% during the 3rd quarter. James J. Burns & Company LLC now owns 1,876 shares of the company’s stock valued at $491,000 after buying an additional 120 shares in the last quarter. Finally, Winthrop Advisory Group LLC lifted its position in shares of AbbVie by 2.9% during the 3rd quarter. Winthrop Advisory Group LLC now owns 5,088 shares of the company’s stock valued at $1,331,000 after buying an additional 144 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts have weighed in on ABBV shares. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and upped their price objective for the stock from $235.00 to $300.00 in a research report on Thursday, August 13th. BNP Paribas Exane increased their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Scotiabank lifted their target price on shares of AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a research report on Tuesday, October 6th. Morgan Stanley boosted their target price on shares of AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Finally, BMO Capital Markets upped their price target on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $279.86.
View Our Latest Research Report on ABBV
AbbVie Stock Performance
NYSE:ABBV opened at $286.10 on Thursday. AbbVie Inc. has a one year low of $190.75 and a one year high of $291.40. The stock has a market cap of $505.47 billion, a PE ratio of 80.82, a P/E/G ratio of 1.30 and a beta of 0.24. The stock has a 50 day moving average price of $268.20 and a 200 day moving average price of $236.51.
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts predict that AbbVie Inc. will post 13.92 earnings per share for the current fiscal year.
AbbVie Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.
Insider Activity at AbbVie
In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.
Trending Headlines about AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie submitted a Biologics License Application to the FDA for etentamig, a monthly-dosed BCMA x CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. The Phase 3 CERVINO study reportedly delivered statistically significant improvements in overall response rate and progression-free survival versus standard therapies, adding a potential growth product to AbbVie’s oncology pipeline. AbbVie Submits BLA for Etentamig
- Positive Sentiment: AbbVie’s growth drivers remain in focus. Skyrizi and Rinvoq are expected to help offset Humira’s decline, while the FDA’s approval of a subcutaneous induction option for Skyrizi in Crohn’s disease could improve convenience and broaden adoption through at-home treatment. Skyrizi Crohn’s Disease Approval
- Neutral Sentiment: Investors are preparing for AbbVie’s third-quarter results, with attention on Skyrizi and Rinvoq sales, expense trends, updated guidance, and the sustainability of earnings growth. The company previously reported quarterly revenue and adjusted earnings above consensus expectations.
- Negative Sentiment: Analysts continue to debate whether ABBV is fully valued after a strong rally. Its elevated valuation leaves less room for disappointment, while rising expenses, softer estimates, and intensifying competition could pressure near-term results. AbbVie Patent Cliff Analysis
- Negative Sentiment: The company’s dividend appeal faces a longer-term test as investors seek evidence that Skyrizi and Rinvoq can replace lost Humira revenue and support continued payout growth. High Treasury yields also make income-oriented stocks compete harder for investor capital.
About AbbVie
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.
The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.
Featured Articles
- Five stocks we like better than AbbVie
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
